Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
about
Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapyCurrent and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancerPrognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effectiveMRI in breast cancer therapy monitoringDCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapyEarly complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.NEO adjuvant chemotherapy in breast cancer: What have we learned so far?Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy.Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detectionPre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewQuantitative discrimination between invasive ductal carcinomas and benign lesions based on semi-automatic analysis of time intensity curves from breast dynamic contrast enhanced MRI.Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer.Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model.Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer.Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy.A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response.Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.Analyzing Spatial Heterogeneity in DCE- and DW-MRI Parametric Maps to Optimize Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Molecular and functional imaging of breast cancer.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapyMagnetic resonance imaging and spectroscopy: how useful is it for prediction and prognosis?Breast MRI: guidelines from the European Society of Breast Imaging.Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients.Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.MRI and ¹⁸F-FDG PET/CT in monitoring the response to neoadjuvant chemotherapy: is it necessary to appropriately select the patients?Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?
P2860
Q27027281-64CF417F-822F-4B9F-9DB5-763DB3D24812Q30460977-4B84C010-AC5C-409D-B325-C073E18EC625Q33474971-41467CDE-DFF3-4FC2-87EF-BD27BC345183Q33593185-2AFA41C9-E711-41D9-B5D9-4EFAA9E44D90Q33938324-2C0AAAEB-3A20-4B59-BD36-63E7633AE26AQ34066039-B936C508-C78B-43AA-9359-5A779272E151Q34132992-582C7991-DB22-4880-B0E4-19BE6B5AFE76Q34138174-C650A025-CE07-4E6F-A8BB-5FEF05B3E2BDQ34189855-8A10CE56-64CC-490B-9D12-854AD7B1EB4EQ34392087-D43B2ADE-9CBF-4DCE-895F-5E7965B40071Q34415629-6CAB7028-42EC-481C-B2B9-537C817CC195Q34566213-47911A89-6F57-4263-AE18-C5A0BC2E98AFQ35162631-062736A1-56DF-4AEC-A1E5-3A03898D26C4Q35754699-FE96F8F9-E387-4386-AECE-45690BA9236CQ35794860-23341ED2-AEA9-4188-935D-99AA01DA42E5Q35984544-6B0FDCFA-1497-4131-A5D3-76D2825AA03DQ36296828-83F08EBD-0D7B-4CEC-93F3-AD1E646616C0Q36614796-03B05181-BCE1-474A-BF31-5B2FEEF4AD93Q36694909-2F9D2D39-2B58-48BC-B83F-7AB11C1E2622Q37093041-BFC14B33-41AF-4654-AB1C-71F97E56B0BDQ37385321-F01EF76F-44C8-471C-AC03-D82A3DF4EC50Q37389806-E1443A23-C735-4840-9273-1AA177479340Q37612288-3C3DF80F-CFEC-4377-9B3E-1E8C7BB6D376Q37642829-CBD22583-3A28-4EB1-BA09-FF9C5129E95FQ37721539-B0088177-246D-4340-B2AF-967FBDB46358Q37776141-68DCA0AD-449A-4631-8EE2-ABC9B810E3ADQ38000076-5C6F68DC-5C83-4835-95C3-04EC52C0DD05Q38808843-E3C90DAC-EC31-43B8-967B-147783CE95BAQ41829224-75FD78D8-8EA5-4A00-A705-DFEC93B4D283Q43066187-60962B45-55B3-4167-983A-9B391326E712Q46525479-5EED694D-81B0-43EB-9473-B81A7D72C0CBQ46712956-DCC88549-A89A-435D-B6C0-690BF578047DQ47992763-6E5B888E-56EC-4F9D-B18D-D1C9D98CBE5DQ53063792-E3AD9132-6E10-4D0F-9C46-F3F0BB740F9EQ53080309-67600D5C-C933-48FB-87A4-39ACABC52B0AQ53213556-81DE19E4-AB2C-4B09-9B6A-096B067416A6
P2860
Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Monitoring the size and respon ...... cin) with serial enhanced MRI.
@en
Monitoring the size and respon ...... rs to neoadjuvant chemotherapy
@nl
type
label
Monitoring the size and respon ...... cin) with serial enhanced MRI.
@en
Monitoring the size and respon ...... rs to neoadjuvant chemotherapy
@nl
prefLabel
Monitoring the size and respon ...... cin) with serial enhanced MRI.
@en
Monitoring the size and respon ...... rs to neoadjuvant chemotherapy
@nl
P2093
P356
P1476
Monitoring the size and respon ...... icin) with serial enhanced MRI
@en
P2093
Chien-Sheng Tsai
Hsien-Kun Chang
Min-Ying Su
Shih-Cheh Chen
Swei Hsueh
Yun-Chung Cheung
Yung-Chang Lin
P2860
P2888
P356
10.1023/A:1022153327339
P407
P50
P577
2003-03-01T00:00:00Z
P5875
P6179
1012608981